- HEPATITIS B CORE PROTEIN MODULATORS
-
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:
- -
-
Page/Page column 47; 142; 143
(2018/04/13)
-
- PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS
-
The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.
- -
-
Page/Page column 21; 22
(2018/10/19)
-
- HEPATITIS B CORE PROTEIN MODULATORS
-
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
- -
-
Paragraph 00076
(2017/04/11)
-
- 11-OXO-10,11-DIHYDRODIBENZO[B,F][1,4]THIAZEPINE S-OXIDE DERIVATIVES AND THEIR USE AS DOPAMINE D2 RECEPTOR ANTAGONISTS
-
The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.
- -
-
Paragraph 0103
(2015/02/25)
-
- HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
-
ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
- -
-
Paragraph 00077
(2015/10/05)
-
- Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists
-
The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders. However, clinically approved drugs targeting D2 DAR display poor selectivity between the D2 and other receptors, especially the D3 DA
- Xiao, Jingbo,Free, R. Benjamin,Barnaeva, Elena,Conroy, Jennie L.,Doyle, Trevor,Miller, Brittney,Bryant-Genevier, Marthe,Taylor, Mercedes K.,Hu, Xin,Dulcey, Andrés E.,Southall, Noel,Ferrer, Marc,Titus, Steve,Zheng, Wei,Sibley, David R.,Marugan, Juan J.
-
p. 3450 - 3463
(2014/05/20)
-
- Evaluation of NTF1836 as an inhibitor of the mycothiol biosynthetic enzyme MshC in growing and non-replicating Mycobacterium tuberculosis
-
The mycothiol biosynthesis enzyme MshC catalyzes the ligation of cysteine with the pseudodisaccharide GlcN-Ins and has been identified as an essential enzyme in Mycobacterium tuberculosis. We now report on the development of NTF1836 as a micromolar inhibi
- Newton, Gerald L.,Buchmeier, Nancy,La Clair, James J.,Fahey, Robert C.
-
experimental part
p. 3956 - 3964
(2011/08/06)
-